CMC Pharmaceuticals
Private Company
Funding information not available
Overview
CMC Pharmaceuticals is a specialized CDMO focused on providing end-to-end Chemistry, Manufacturing, and Controls (CMC) services for small molecule drug development. Founded in 2016 and based in Boston, the company distinguishes itself through a highly collaborative, flexible partnership model that prioritizes early-stage development to de-risk client programs. It serves a diverse client base from startups to large pharma and government programs, offering integrated scientific, regulatory, and manufacturing oversight services designed to accelerate development and navigate regulatory pathways efficiently.
Technology Platform
Integrated CMC service model providing formulation development, analytical services, stability testing, regulatory strategy, and manufacturing oversight for small molecule drugs, without proprietary technology lock-in.
Opportunities
Risk Factors
Competitive Landscape
CMC Pharma competes in the fragmented CDMO market, differentiating itself through a flexible, partnership-focused model for early-stage development, as opposed to large CDMOs focused on commercial manufacturing or niche players offering only isolated services like analytical testing or consulting.